Creation of Bone Marrow Microenvironment for Treatment of MDS in Conjunction With Allogeneic Stem Cell Transplantation
Phase 2
18 Years
N/A
18 Years
N/A
Not Enrolling
Both
Myelodysplastic Syndromes, Myelofibrosis
Both
Myelodysplastic Syndromes, Myelofibrosis
Trial Information
Creation of Bone Marrow Microenvironment for Treatment of MDS in Conjunction With Allogeneic Stem Cell Transplantation
Inclusion Criteria:
- Patients with impaired marrow stem cells by cytogenetic analysis or morphology
(blasts), considered normal candidates for allogeneic BMT. Such patients will also be
entitled to allogeneic bone marrow transplantation with intraosseous DBM.
- Patients with documented myelofibrosis will be entitled to allogeneic bone marrow
transplantation with intraosseous DBM.
Exclusion Criteria:
- Patients with anticipated life expectancy of < 4 weeks.
- Pregnant or lactating women.
- Patients with an unrelated disease or relevant clinical problem that may not permit
evaluation of the results of the study.
- Patients under 18 years old.
Type of Study:
Interventional
Study Design:
Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label
Outcome Measure:
Enhancement of hematopoiesis in patients with myelofibrosis MDS by intraosseous demineralized bone matrix together with allogeneic bone marrow transplantation (BMT)
Principal Investigator
Olga Gurevitch, PhD
Investigator Role:
Study Director
Investigator Affiliation:
Hadassah Medical Organization
Authority:
Israel: Israeli Health Ministry Pharmaceutical Administration
Study ID:
220202-HMO-CTIL
NCT ID:
NCT00148980
Start Date:
April 2003
Completion Date:
Related Keywords:
- Myelodysplastic Syndromes
- Myelofibrosis
- Myelodysplastic syndrome (MDS)
- Allogeneic stem cell transplantation
- Demineralized bone matrix (DBM)
- Bone marrow microenvironment
- Primary Myelofibrosis
- Myelodysplastic Syndromes
- Preleukemia
Name | Location |
|---|
